Vera Therapeutics, Inc. (VERA)
Fuera de horario:
Vera Therapeutics, Inc.
8000 Marina Boulevard
Suite 120
Brisbane, CA 94005
United States
650 770 0077
https://veratx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 51
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Marshall W. Fordyce M.D. | Founder, President, CEO & Director | 910.14k | N/D | 1975 |
| Mr. Sean P. Grant M.B.A. | Chief Financial Officer | 642k | N/D | 1985 |
| Mr. Joseph R. Young M.B.A. | Senior VP of Finance & Chief Accounting Officer | N/D | N/D | 1973 |
| Mr. Julien E. Capers J.D. | VP & Head of Legal | N/D | N/D | N/D |
| Ms. Kelly Rauber | VP & Head of Human Resources | N/D | N/D | N/D |
| Mr. Tom Doan | Senior Vice President of Development Operations | N/D | N/D | 1972 |
| Ms. Lauren Frenz | Chief Business Officer | N/D | N/D | 1985 |
| Dr. Neeraj Pakala M.B.A., Ph.D. | Senior VP and Head of Product Development & Manufacturing | N/D | N/D | N/D |
| Dr. Kerry Cooper M.D. | Senior Vice President of Medical Affairs | N/D | N/D | N/D |
| Dr. Robert M. Brenner M.D. | Chief Medical Officer | N/D | N/D | 1968 |
Descripción
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Vera Therapeutics, Inc. a partir del 1 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 8; Junta: 5; Derechos del accionista: 8; Compensación: 8.
